Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
- 28 December 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 31 (1) , 23-29
Abstract
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection (LRTI) in infants and young children. Palivizumab is a RSV-specific prophylactic for use in high-ri...Keywords
This publication has 80 references indexed in Scilit:
- Respiratory Syncytial Virus Entry Inhibitors Targeting the F ProteinViruses, 2013
- The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and ComplementJournal of Virology, 2012
- Therapeutic targeting of respiratory syncytial virus G-proteinImmunotherapy, 2010
- The cost effectiveness of palivizumab: a systematic review of the evidenceJournal of Medical Economics, 2010
- Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in MiceJournal of Virology, 2010
- Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programmingNature Medicine, 2009
- The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing LeukocytesJournal of Virology, 2008
- Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta inductionInternational Immunology, 2008
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Appearance of a Soluble Form of the G Protein of Respiratory Syncytial Virus in Fluids of Infected CellsJournal of General Virology, 1987